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Abstract
Atherosclerosis (ATS) has been considered to be a degenerative disease affecting large and 
medium-sized arteries, resulting in a passive build-up of cholesterol in the artery wall. 
In the last decade, immune system was proved to play the key role in the pathogenesis 
of ATS, suggesting ATS to be more progressive and accelerated in chronic inflammatory 
conditions. Studies in patients with autoimmune diseases, particularly in the most preva-
lent ones such as rheumatoid arthritis and systemic lupus erythematosus, confirmed the 
significantly more serious atherosclerotic disease and increased cardiovascular (CV) risk 
compared to the general population, suggesting these diseases as an independent risk 
factor for CV diseases. There are only few studies evaluating ATS and CV risk in systemic 
sclerosis (SSc). Moreover, these studies present contradictory results. Furthermore, it is 
complicated to differentiate primary vascular affection related to the pathogenesis of SSc 
from the secondary vascular infliction due to ATS. Nevertheless, most of the studies to 
date suggest ATS and its clinical manifestations to be more prevalent in SSc. Future stud-
ies evaluating larger cohorts of patients are required to determine the relevance of ATS 
and CV disease and management of these comorbidities in SSc.
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1. Introduction
Accelerated atherosclerosis (ATS) with increased cardiovascular (CV) morbidity and mor-
tality is a well-known complication of many systemic inflammatory diseases such as sys-
temic lupus erythematosus (SLE) and rheumatoid arthritis (RA) [1], resulting in higher 
rates of CV morbidity and mortality compared to general population [2, 3]. Therefore, 
ischemic heart disease secondary to coronary ATS is the leading cause of CV mortality in 
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RA patients and in late stages of SLE (while intercurrent infections are the leading cause 
in early disease) [4].
There is emerging data that the same process of early accelerated ATS occurs in systemic scle-
rosis (SSc). Epidemiological studies suggest that a cardiac cause contributes to approximately 
one-third of the non-SSc-related deaths. Moreover, deaths from CV causes occur in SSc more 
than a decade earlier than in the general population [5, 6].
In the 1960s and 1970s, the main cause of death in SSc was scleroderma renal crisis (SRC), 
whereas clinically manifested ATS was rare in SSc patients, and CV involvement was 
most likely the result of vasospasm of coronary arteries. Thanks to recent advances in 
the treatment of SRC and pulmonary arterial hypertension (PAH), causes of mortality in 
SSc have changed. The prevalence of ATS has increased according to recent studies in SSc 
patients [7–9].
Novel laboratory markers of ATS and non-invasive tools to evaluate subclinical coronary ATS 
and peripheral artery disease (PAD) have been described. Most of these are used mainly in 
experimental settings, because of their cost and only partially clear significance of some bio-
markers [10].
2. Atherosclerosis
Atherosclerosis (ATS) is a chronic multifactorial process evolving in the medium and large 
arteries. It figures as a leading cause of cardiac and non-cardiac-related morbidity and mor-
tality worldwide [1]. According to the World Health Organization (WHO) definition, it is 
a variable combination of changes of the innermost layer of the artery—the intima and is 
associated with deposits of lipids (mainly cholesterol particles), polysaccharide molecules, 
and blood elements. The traditional view suggests that ATS results from a passive build-up of 
cholesterol in the artery wall [11]. In fact, it is a multifactorial disease that can be considered 
an immune/inflammatory response of intima to tissue damage [4].
Inflammation is a key component of ATS [12]. Even a relatively minor elevation of inflam-
matory markers (such as C-reactive protein, CRP) is predictive of CV events in the general 
population [13]. In ATS, endothelial cell dysfunction is the common pathway by which factors 
(such as elevated low-density lipoprotein (LDL), hypertension, diabetes mellitus, elevated 
plasma homocysteine, various infectious agents, and exposure to free radicals from smoking) 
are proposed to contribute to pathogenesis [12]. Endothelial dysfunction leads to upregula-
tion of adhesion molecules on the endothelium and increased vessel wall permeability, which 
enables the accumulation of the foam cells, that is, lipid-laden monocytes and macrophages. 
Migration and proliferation of vascular smooth-muscle cells lead to remodeling of the vessel 
wall and atherosclerotic plaque formation [12].
Cardiovascular diseases (CVDs) have become the most frequent cause of death globally [14]. 
Myocardial infarction (MI) and ischemic stroke caused by ATS dominate the mortality and 
disability statistics in all regions of the world [15].
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3. Atherosclerosis in rheumatic diseases
Early ATS associated with autoimmune diseases is not fully explained by traditional risk fac-
tors such as obesity, smoking, or hyperlipidaemia [16–19]. The acceleration of ATS may be 
attributed (beside the traditional CV risk factors) also to systemic inflammation and use of pro-
atherogenic drugs (Table 1) [2]. In addition, various cellular and cytokine pathways have been 
implicated in the pathogenesis of ATS, as an immuno-inflammatory disease [2, 12, 20–25]. The 
hyperactivation of the immune system leads to premature ATS, contributes to the formation of 
atherosclerotic plaque [3], and earlier occurrence of ATS clinical manifestations [4].
There is heterogeneity with respect to autoimmune-inflammatory risk factors. Cytokines, 
such as tumor necrosis factor alpha (TNF-α), and immune complexes are primarily 
involved in arthritis, such as RA, ankylosing spondylitis (AS) and psoriatic arthritis (PsA), 
as well as in SLE. On the other hand, autoantibodies including anti-oxidized low-density 
lipoproteins (anti-oxLDL), anti-cardiolipin (anti-CL), and anti-beta-2-glycoprotein I (anti-
β2GPI) are rather involved in SLE and antiphospholipid syndrome (APS)-associated vas-
cular conditions [26].
Autoimmune rheumatic diseases characterized by systemic inflammation and accelerated ATS are 
associated with various types of vasculopathies [12, 20, 27]. The characteristics of vasculopathies 
may significantly differ depending on the underlying disease. While classical accelerated ATS has 
Traditional risk factors Disease (inflammation) related risk factors
Age Disease duration
Smoking Smoking (RA, SLE)
Hyperlipidaemia Acute phase reactants (CRP, fibrinogen)
Diabetes mellitus Autoantibodies (APL, anti-oxLDL, anti-Hsp, etc.)
Obesity Pro-atherogenic cytokines (e.g. TNF-α, IL-1, IL-6)
Sedentary life style Chemokines
Endothelial adhesion molecules (ICAM-1, VCAM-1, 
E-selectin)
Therapy-related risk factors Proteases
Methotrexate (bimodal) Hyperhomocysteinemia, low vitamin B12, and folate
Corticosteroids (bimodal) Hyperprolactinemia
Adipokines (resistin, adiponectin, leptin)
Acronyms: RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; CRP, C-reactive protein; APL, antiphospholipid 
antibodies; anti-oxLDL, anti- oxidized low-density lipoprotein antibodies; anti-Hsp, anti-heat shock protein antibodies; 
TNF-α, tumour necrosis factor α; IL-1, interleukin-1; IL-6, interleukin-6; ICAM-1, intercellular adhesion molecule-1; 
VCAM-1, vascular cell adhesion molecule-1.
Adapted from: Soltész et al. [26].
Table 1. Risk factors for atherosclerosis and cardiovascular diseases.
Atherosclerosis and Cardiovascular Risk in Systemic Sclerosis
http://dx.doi.org/10.5772/67495
25
been associated with RA and SLE, obliterative vasculopathy may be characteristic for SSc. All of 
these diseases greatly differ in vascular pathomorphology and function (Table 2) [24, 28–56].
4. Atherosclersis in SSc
Systemic sclerosis (SSc) is a multi-system autoimmune disease characterized by immune 
dysregulation, vasculopathy, and fibrosis. In the pathogenesis, three hallmarks have been 
proposed to play the key role: (1) vasculopathy with the pathognomonic microvascular 
involvement; (2) fibrosis of skin and visceral organs; (3) systemic inflammation characterized 
by the presence of circulating autoantibodies and pro-inflammatory cytokines [57, 58].
The etiology of ATS in SSc is unknown. It may be secondary to concomitant multiple fac-
tors, including traditional CV risk factors, increased endothelial damage, and disease-specific 
immunologic and autoimmune factors, which may contribute to both induction and progres-
sion of ATS [2, 8, 53, 59–61].
Numerous inflammatory mediators implicated in the pathogenesis of ATS, including TNF-α, 
interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP), have been demonstrated 
to be increased in patients with SSc compared with controls [62]. The relationship between 
these mediators and CVD in SSc is unclear. However, chronic systemic inflammation prob-
ably promotes accelerated ATS. Nevertheless, the level of inflammation in SSc is lower than in 
RA and SLE, thus the atherosclerotic process may not be so aggressive and easily detectable 
in small-number studies [63].
Involvement of the microvasculature is one of the earliest features of SSc, preceding and 
potentially contributing via tissue ischemia to the widespread fibrosis characteristic of this 
condition. Pathological changes include disruption of the endothelium, mononuclear cell 
infiltration of the vessel wall, frank obliterative lesions, and progressive loss of capillaries.
Endothelial dysfunction in the capillaries and arterioles, common in SSc, results in disturbed 
vasomotor regulation [64].
Although macrovascular disease was not originally considered as a feature of SSc, multiple 
studies have revealed an increased prevalence of large-vessel disease of the upper and lower 
Leading mechanisms Disease
Accelerated atherosclerosis RA, SpA, SLE, APS (SSc)
Autoantibody-mediated mechanisms SLE, APS, RA
Proliferative obliteration SSc, MCTD
Acronyms: RA, rheumatoid arthritis; SpA, spondyloarthritis; SLE, systemic lupus erythematosus; APS, anti-phospholipid 
syndrome; SSc, systemic sclerosis; MCTD, mixed connective tissue disease
Adapted from: Soltész et al. [26].
Table 2. Different vascular pathogenesis in autoimmune rheumatic diseases.
Systemic Sclerosis26
limbs in patients with SSc [65, 66]. The prevalence of coronary artery and cerebrovascular 
disease in SSc, however, remains to be elucidated.
4.1. Prevalence of atherosclerosis in SSc
Mortality in SSc was described to be approximately three times increased as compared to the 
general population, in particular due to cardiopulmonary complications, including pulmo-
nary arterial hypertension (PAH) and interstitial lung disease (ILD) [67]. The 10-year survival 
of SSc has improved significantly from 54% (1972–1981) to 66–82% (1982–1991), largely due to 
the early diagnosis and treatments available for PAH and scleroderma renal crisis (SRC) [68]. 
Emphasis has thus shifted to comorbidities in SSc, such as ATS, that may affect the long-term 
outcomes of SSc [68] with the substantially increased death rates due to atherosclerotic CVD 
or cerebrovascular disease [63]. Currently, CV-related deaths are responsible for a 20–30% 
mortality rate in SSc patients [63].
In particular, the 2010 survey from the European League Against Rheumatism Scleroderma 
Trials and Research (EUSTAR) database estimated that 26% of SSc-related causes of death 
were due to cardiac causes (mainly heart failure and arrhythmias) and 29% of non-SSc-related 
causes of death were due to ATS and CV causes [69].
There are contradictory reports regarding the prevalence of ATS in SSc [70]. According to 
some authors, the prevalence of ATS of the large epicardial coronary arteries is similar to that 
of general population [71].
The prevalence of primary cardiac involvement in SSc is variable and difficult to determine 
because of diversity of cardiac manifestations, presence of subclinical periods, type of applied 
diagnostic tools, and differences in patient populations [10].
Raynaud’s phenomenon, PAH, and SRC represent the main clinical manifestations of micro-
vascular damage (involvement) in SSc, characterized by both vasospasm and structural 
alterations, pathognomonic features of SSc. All these components are thought to predict mac-
rovascular ATS over time [70, 72].
4.2. Risk factors for atherosclerosis in SSc
There is limited data regarding the prevalence of traditional CV risk factors in SSc. Their 
prevalence has been found to be either similar [73, 74] or reduced [75–77] when compared 
with general population. The majority of these studies showed a similar distribution of CV 
risk factors between SSc patients and controls, thereby suggesting that other factors may con-
tribute to the increased prevalence of CV disease in SSc [77].
In addition to age [75, 77], hypercholesterolaemia [75–77], male gender [77], hypertension 
[78], and diabetes [78], SSc appears to be an independent risk factor for coronary artery dis-
ease (CAD) after adjustment for traditional risk factors [73, 78], including the SSc-related fac-
tors: PAH [75, 77], renal involvement [76], and disease duration [75]. Moreover, particularly 
the disease duration, in addition to age and LDL levels, can act as an independent determi-
nant for more severe coronary calcification [75]. Renal involvement in SSc relates to ischemic 
heart disease (after exclusion of the impact of age) [76].
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Studies mostly failed to show an increased frequency of obesity, hyperlipidaemia, hyper-
tension (there was no difference in blood pressure on 24-hour ambulatory blood pressure 
monitoring [79]), and diabetes in SSc [7, 73, 75, 79]. These findings were confirmed also in the 
Australian Scleroderma Cohort Study [77]. Moreover, significantly lower cholesterol levels 
and diastolic blood pressure were described in SSc compared to controls [75]. On the other 
hand, one study revealed a slight increase in blood pressure and fasting glucose and a lower 
BMI in SSc population [80].
Factors contributing to ATS in SSc, beside the traditional risk factors, include chronic inflam-
mation, increased levels of CRP and homocysteine, autoantibodies, deranged lipid function 
and profile, corticosteroid treatment, increasing age and disease duration [40, 65, 66, 81]. 
Beside these factors, there is also association with the dysfunction of the coagulation and 
fibrinolytic system and increased production of adhesion molecules [82–86]. Specifically, cor-
ticosteroids and immunosuppression seem not to be associated with the risk of CAD [76].
Results from studies on lipids are contradictory. Lipid metabolism seems to be altered and 
accompanied by lower levels of high-density lipoprotein (HDL) [87] or significantly elevated 
lipoprotein(a) (LpA) without any significant difference in other cholesterol parameters [88]. 
High levels of LpA in SSc are usually associated with increased CV risk [88]. In addition, high 
levels of LpA adversely affect the effect of thrombosis, due to reduced fibrinolysis [88, 89]. Of 
interest, the presence of anti-centromere antibodies (ACA) is associated with decreased lev-
els of HDL [87]. SSc patients may have some higher detected pro-inflammatory-HDL levels 
(representing an increased risk for ATS) [74]. Of note, increased IgG autoantibody against the 
lipoprotein lipase (anti-LPL) in SSc (detected in 24% of SSc patients) may cause elevation of 
triglyceride (TG) levels [90]. On the other hand, some studies have not described any altera-
tion of the components of the lipid profile in SSc patients [88].
Some novel CV risk factors have been reported to be elevated in SSc, such as oxidized low-
density lipoprotein (oxLDL) and endothelin [7]. In terms of pro-thrombotic state in SSc, the 
coagulation system can be activated, and fibrinolysis can be impaired [89].
4.3. Pathogenesis and risk factors specific for SSc
Pathogenesis of SSc is characterized by inflammatory, vascular, and fibrotic events. It primar-
ily affects the microvessels (e.g. Raynaud’s phenomenon); however, macrovascular oblitera-
tive disease has also been described in SSc [40, 42, 70, 82, 83, 91].
Endothelial dysfunction, one of the earliest events in the pathogenesis of SSc and vasculopathy, 
is critical in the development of ATS, and represents a loss in vasodilatory function, together 
with increased platelet aggregation and leukocyte adhesion due to decreased nitric oxide (NO) 
as a key vasodilator [92]. Endothelial injury results in lumen occlusion and tissue hypoxia. 
The histopathological picture of scleroderma includes intima proliferation, the proliferation 
of endothelial and smooth muscle cells, destruction of internal elastic lamina and transmural 
lympho-plasmocytic infiltration of the vessel wall. Thus, vasculopathy in SSc does not rep-
resent the classical ATS but rather an obliterative vasculopathy [40, 82]. This has been docu-
mented by reports of very severe clinical cases of obliterative peripheral artery disease (PAD) 
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despite the lack of traditional risk factors for ATS. About 15–20% of scleroderma patients exert 
multiple vascular abnormalities including the combination of CVD, stroke and PAD [2, 70, 82].
In addition, ischemia, oxidative stress, and oxLDL may trigger inflammation in the vessel 
wall. Homocysteine levels correlate with the development of macrovascular disease and 
PAH, and decreased vitamin B12 release in SSc [83].
Regarding vascular pathogenesis, the possible role of methylene-tetrahydrofolate reductase 
(MTHFR) gene C677T polymorphism was described in the development of macrovascular 
manifestations of SSc [83].
4.4. Mechanisms of endothelial damage
Vascular endothelium as a functionally remarkable organ regulates coagulation, fibrinolysis, 
permeability, vasomotion, and inflammation. Clinical and pathological features of vascular 
damage and endothelial cell activation represent an important hallmark of SSc vasculopathy, 
even in the absence of other concomitant risk factors [10]. Endothelial dysfunction is a compo-
nent of the pathophysiology of both SSc and ATS. In SSc, the initiating injury is unknown [72].
Endothelial cell damage leads to enhanced expression of adhesion molecules and elevated 
levels of circulating soluble adhesion molecules, such as soluble E-selectin, intercellular adhe-
sion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1), which are all 
significantly increased in SSc, reflecting endothelial activation [93]. This results into adhesion 
of inflammatory cells, trans-migration across the vessel wall, and infiltration of the extracel-
lular matrix.
Different mechanisms may induce and perpetuate endothelial dysfunction, which contributes 
to the pathogenesis of atherosclerotic risk, and progressive vasculopathy in SSc. The main 
pathogenic mechanisms underlying endothelial damage have been proposed: (1) dysregula-
tion of vascular tone, as a consequence of an imbalance between vasoconstrictor and vasodi-
lator mediators; (2) defective angiogenesis; (3) injury/activation elicited by the activation of 
innate and adaptive immune response; and (4) functional defects of endothelial progenitor 
cells (EPCs) [94, 95].
1) The important component of endothelial dysfunction in SSc is derangement of vasoactive 
mediators, with an increase in vasoconstrictive endothelin and a decrease in the vasodila-
tor nitric oxide (NO) [93]. In addition, increased levels of endothelin, the most potent vaso-
constrictive peptide released from the endothelial layer, play a pivotal role in endothelial 
dysfunction in both SSc and ATS [96]. An impairment of endothelium-dependent vasodi-
lation occurs before the onset of clinical ATS in SSc [40].
2) Although there is an increased circulation of angiogenic factors, such as vascular endothe-
lial growth factor (VEGF) [97], a reduction in the density of blood vessels is one of the 
hallmarks of vascular disease in SSc [97]. Abnormal angiogenesis results from increased 
VEGF, which is stimulated particularly by severe tissue hypoxia associated with chronic 
blood flow reduction in SSc. This leads to a condition of defective vascularization. There 
is also a reduction in circulating EPCs [98–100]. Moreover, the up-regulation of VEGF also 
Atherosclerosis and Cardiovascular Risk in Systemic Sclerosis
http://dx.doi.org/10.5772/67495
29
contributes to the development of fibrosis in both inflammatory and non-inflammatory 
stages of the disease [101].
3) In the early stage of scleroderma, the endothelial cell layer of microcirculation is activated 
and/or injured by unknown and various mechanisms, including infection-induced apop-
tosis, immune mediated cytotoxicity, anti-endothelial antibodies, or ischemia-reperfusion 
injury [96].
4) In particular, new blood vessels may form as a consequence of endothelial sprouting from 
pre-existing endothelial cells (angiogenesis) or as peripheral recruitment of bone marrow-
derived circulating EPCs. EPCs contribute, at least in the early stage of the disease, to 
vascular healing by homing in the damaged endothelium [102].
5. Components involved in the atherogenesis in SSc
5.1. Endothelial progenitor cells
The elevation of endothelial progenitor cells (EPCs) in early disease is followed by its decrease 
during the disease duration [103], suggesting a probable exhaustion of the precursor endothe-
lial pool during disease course. A decreased number of EPCs in the peripheral circulation has 
been shown to be predictive of recurrent acute coronary artery events [104]. Moreover, a low 
number of circulating EPCs seems to characterize a more active disease phenotype, identified 
by a higher risk of digital vascular lesions and higher severity score. Scleroderma circulating 
EPCs are characterized by a defective functional phenotype with consequent defective migra-
tory activity and impaired recruitment to ischemic damaged tissue [100, 105–107].
The true significance of EPCs as a potential biomarker of both CV risk and SSc disease activity 
is not determined. It is not clear whether the cells are true progenitor cells [99] that incorpo-
rate into new blood vessels or rather cells of hematopoietic lineage, which have a paracrine 
effect on blood vessel formation [108]. Assessment of EPCs levels in SSc may be conflicting 
mainly because of the different methods of detection [109, 110].
5.2. Circulating endothelial cells
Circulating endothelial cells (CECs) are released into the systemic circulation after detach-
ment of cells from basement membrane in response to endothelial injury. Increased number 
of CECs, a novel marker of endothelial damage, has been demonstrated not only in patients 
with myocardial infarction (MI), unstable angina, peripheral vascular disease (PAD), but also 
in SSc, suggesting their role as a marker of chronic endothelial damage [111, 112].
5.3. Antibodies against the anti-oxidized low-density lipoproteins (anti-oxLDL)
Patients with diffuse cutaneous SSc (dcSSc) were found to have higher levels of anti-oxidized 
LDL (oxLDL) antibodies [113], the titer of which correlates with the severity of ATS as well as 
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with CV complications [114]. In addition, higher levels of circulating complexes of anti-beta-
2-glycoprotein I (anti-oxLDL/β2GPI), considered as pro-atherogenic, were demonstrated in 
SSc as well [115, 116].
5.4. Antiphospholipid antibodies
Anti-β2-glycoprotein I (anti-β2GPI) in the presence of anticardiolipin (aCL) antibodies 
could be independently predictive of incident ischemic stroke and MI over 20 years of 
follow-up [117]. The prevalence of aCL and anti-β2GPI antibodies occurring in the absence 
of typical clinical manifestations of antiphospholipid syndrome (APS) has been demon-
strated to be increased in patients with SSc compared to controls [118]. Anti-β2GPI is asso-
ciated with both higher mortality and vascular disease, including digital ischemia and 
PAH, in SSc [119].
5.5. Anti-endothelial cell antibodies
Elevated anti-endothelial cell antibodies (AECA) correlate with increased subclinical ATS in 
non-rheumatic patients [120], SLE patients [121], and may contribute to an increased risk of 
early ATS in SSc, similarly as elevated levels of ICAM-1 [122]. However, in general the levels 
of AECA do not always have to be increased in all cases of chest pain and atherosclerotic 
involvement of the coronary arteries (compared with patients with chest pain and normal 
coronary angiography) [123]. The presence of circulating antibodies with anti-endothelial 
activity in scleroderma patients may be considered as an adjunctive mechanism associated 
with chronic endothelial damage [109, 110].
5.6. Angiotensin converting enzyme gene polymorphism
Polymorphism (insertion or deletion, I/D) of the angiotensin converting enzyme (ACE) gene 
can be another factor possibly influencing ATS. The highest levels of plasma ACE are associ-
ated with the DD genotype and the lowest levels are associated with the II genotype [124]. The 
D allele of the ACE gene, associated with ATS severity [125], has an increased frequency in SSc 
[2]. The risk of MI in patients with the DD genotype is higher compared with those with either 
the II or ID genotype [126, 127]. The presence of a D allele in SSc correlates with increased 
carotid intima-media thickness (CIMT) [128].
5.7. Microparticles
Microparticles (MPs), small circulating membrane-coated vesicles, are important mediators 
of intercellular signaling arising from a variety of cell types. MPs contribute to the immuno-
pathogenesis of various thrombotic and rheumatic diseases via their role in the regulation 
of inflammation, thrombosis, and angiogenesis. MPs have been suggested as a biomarker of 
CAD. High levels result in severe endothelial dysfunction by selectively impairing the pro-
duction of NO and are found in patients with acute MI [129].
MPs levels are also elevated in patients with SSc and correlate with the presence of ILD [130].
Atherosclerosis and Cardiovascular Risk in Systemic Sclerosis
http://dx.doi.org/10.5772/67495
31
6. Types of damage
The main clinical features of atherosclerotic disease in SSc patients are represented by an 
involvement of peripheral, cerebrovascular, carotid, and coronary arteries with consequent 
high risk of peripheral vascular disease, stroke, and coronary heart disease, in particular in 
late disease [131]. SSc is associated with about a twofold increased risk of developing MI and 
stroke, and a fourfold increased risk for peripheral vascular disease, even after adjustment for 
CV risk factors (BMI, smoking, hypertension, diabetes, and hyperlipidaemia). This fact sug-
gests that the increased risk of CV events in SSc may depend on both ATS and non-atheroscle-
rotic factors, such as vasospasm, SSc specific vasculopathy, vasculitis, and thrombosis [73].
Presence of plaques and ischemic arterial events positively correlates with the positivity of 
ACA, while anti-topoisomerase I antibodies (ATA) positivity in SSc is rather associated with 
fewer ischemic events. The antibody profile and different disease subsets are supposed to 
contribute to macrovascular involvement [76].
6.1. Coronary arteries
Even though cardiac disease is a major cause of death in SSc patients, clinical signs of cardiac 
disease are apparent in only 10% [71], mostly appearing late in the course of disease [132], and 
predicting an adverse prognosis [133]. Up to 80% of postmortem evaluation of SSc patients’ 
hearts may reveal a form of cardiac involvement [134].
The prevalence of ATS involving coronary vessels and its clinical manifestation, including 
angina, MI, and sudden death, is difficult to evaluate in SSc, because of the primary car-
diac involvement possibly depending on myocardial damage secondary to microvascular 
alterations, myocardial fibrosis, arrhythmias resulting from the conduction system involve-
ment, and last but not least, pericardial and valvular disease [135]. Myocardial fibrosis in 
SSc patients is considered a hallmark cardiac manifestation [133]. Foci of fibrosis not corre-
sponding to coronary artery distribution were reported in 50% of autopsies conducted on SSc 
patients [136].
Moreover, secondary heart disease due to renal vasculopathy, ILD, and PAH could 
adversely influence cardiac function. Thus, symptoms of cardiac complications could be 
nonspecific, and could overlap with those of other comorbidities. Furthermore, hyperten-
sion, obesity, diabetes, and other comorbidities may contribute to adverse influence on 
cardiac function, mainly in older SSc patients [135].
The risk of acute MI may be 2.45x greater in SSc than in population of the same age, sex, and 
comorbidities [78]. In addition, the impact of SSc on acute MI risk may be even greater than 
that of hypertension (increasing the risk 2.08x), and diabetes (2.14x), while immunosuppres-
sant drugs probably do not reduce this risk of MI [78].
Of note, MI has been described in SSc patients with unaffected coronary arteries. In this set-
ting, microvascular disease leading to ischemic events and contraction band necrosis, resulting 
from both occlusive vascular disease and intermittent vasospasm (the so called “myocardial 
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Raynaud’s phenomenon”), has been demonstrated to be the main mechanism associated with 
myocardial ischemic events in these patients [136]. In addition, epicardial coronary arteries 
in SSc patients have been reported to be free of significant lesions even in the setting of MI, 
congestive heart failure, and sudden cardiac death [137].
On the other hand, while the frequency of epicardial coronary vessel ATS appeared to be 
similar in SSc and general population (48% vs. 43%), the atherosclerotic lesions of the small 
coronary arteries or arterioles occurred significantly more often in SSc patients, compared 
with controls [138].
The coronary vessel involvement was ascertained invasively by coronarography with the con-
clusion, that the prevalence of CAD in SSc patients with suspected CAD was similar to that 
detected in controls [71]. Angiographic abnormalities may be higher than previously thought 
in asymptomatic patients with SSc, including significant coronary artery stenosis, coronary 
artery ectasia, slow flow, tortuosity, calcification, and spasm, and must not be related to tradi-
tional CV risk factors [132]. These abnormalities (demonstrated in asymptomatic female SSc 
patients free from CV risk factors) suggest that coronary artery vasculopathy is common even 
in the absence of classic CV risk factors, supporting the role of SSc as a relevant risk factor for 
CAD [132].
The presence of coronary calcified plaques in SSc patients asymptomatic for angina evaluated 
by computed tomography (CT) coronary angiography confirms the subclinical ATS as a com-
mon one in SSc [139]. In addition, SSc seems to be an independent risk factor for increased 
coronary artery calcium deposition [75].
6.2. Peripheral macrovascular abnormalities in SSc
Macrovascular complications (involving the arms and legs) may be detected even in SSc 
patients with minimal underlying CV risk factors [140]. Peripheral vascular disease (PAD) in 
patients with SSc has been reported to be significantly increased, with use of techniques such 
as the ankle brachial pressure index (ABPI), lower-limb Doppler ultrasound, and angiogra-
phy [140–143]. Similarly, evaluation of the PAD using the WHO questionnaire for intermit-
tent claudication may reveal more frequent impairment in SSc (almost 22%) than in general 
population (4.5%) [65]. PAD diagnosed by the ABPI may reach 17% of patients with SSc (in 
contrast to no healthy control), while there is no difference in the traditional CV risk factor 
profile [66].
Studies have showed a six times increased prevalence of PAD, detected by angiography, 
Doppler ultrasound, or physical examination in patients with limited cutaneous SSc (lcSSc) 
compared to healthy controls [141], and almost five times greater presence of intermittent 
lower limb claudication in SSc, detected by Edinburgh Claudication questionnaire, than the 
prevalence of symptomatic PAD in the general population, as reported by a similar WHO 
claudication questionnaire [65]. According to one study, approximately 4.2% of SSc patients 
(including the ones treated with vasodilators) suffer from clinical intermittent claudication, 
and even may develop ischemic stroke [143]. However, other studies failed to prove the 
increased prevalence of stroke in SSc [7].
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The traditional CV risk factors seem to contribute to proximal, but not distal, vascular disease 
in the lower limb, as demonstrated in angiograms performed in a single SSc cohort [142]. In 
at least some cases, peripheral vascular disease in SSc is not atherosclerotic but related to the 
vasculopathy of SSc itself, which is supported by finding of chronic obliterative thromboangi-
itis on histological examination of an amputated limb [141]. Involvement of the vasa vasorum 
has been suggested as a potential cause of macrovascular disease in SSc [144].
Macrovascular disease, defined as an involvement of blood vessels with an internal diam-
eter >100 microns, is probably associated with the more distal small vessel pathology [96]. 
Morphology and blood flow of the proper palmar digital arteries correlate with nailfold cap-
illary morphology, and progression of microvascular disease (detected by capillaroscopy—
from early capillaroscopy pattern to an active and late capillaroscopy pattern) is linked to 
macrovascular disease. ATA may represent an independent predictive factor for macrovas-
cular damage [145].
6.3. Cerebrovascular disease
Literature data aimed to estimate the prevalence of cerebrovascular disease in SSc and the 
relationship between disease and risk of ischemic stroke is inconclusive [146]. Several studies 
suggested that cerebral disease may be underestimated [147–149]. The prevalence of cerebro-
vascular disease (transient ischemic attack, stroke, carotid or vertebral artery bruits, Doppler 
evidence of carotid or vertebral artery disease, or angiographic evidence of carotid artery 
stenosis) in SSc patients was found to be 1.3-times higher compared to controls [141].
The increased ischemic stroke risk in SSc may be due to different pathogenic mechanisms 
such as vascular injury, chronic inflammation, and vasospasm [146]. SSc may be indepen-
dently associated with a 43% increase in ischemic stroke risk compared to healthy controls 
[73]. This risk is not even modified by commonly employed medications (such as calcium 
channel blockers, angiotensin converting enzyme inhibitors, oral corticosteroids, or immuno-
suppressant drugs) [146].
Cerebral vascular involvement may be caused by endothelial dysfunction, as well as by ATS 
[150]. The role of inflammatory or immune mechanisms can be declared by the apparent 
efficacy of immunosuppressive drugs in stroke treatment [151]. Finally, cerebral vasospasm 
(“Raynaud’s phenomenon-like”) may be associated with transient ischemic attacks or focal 
neurological defects and it is evidenced by reversibility of arterial lesions and absence of spe-
cific histologic findings [152].
Stenosis of carotid arteries, a predictive factor of stroke, is more often found in SSc patients with 
respect to general population with no difference in the traditional CV risk factor profile, sup-
porting the increased risk of stroke in SSc [66]. Moreover, intracerebral vascular calcifications, 
an independent risk factor of ischemic stroke in the general population [153], are significantly 
more prevalent in asymptomatic SSc patients compared to the controls investigated by non-
contrast CT scan [154]. Similarly, white matter hyperintensities on brain magnetic resonance 
imaging (MRI), a known risk factor for future symptomatic stroke [155], are more common in 
asymptomatic SSc patients than in population without autoimmune diseases [156, 157].
Systemic Sclerosis34
Another tool for examining cerebral artery involvement, a single photon emission com-
puted tomography (SPECT), showed focal or diffuse hypoperfusion in mainly neurologi-
cally asymptomatic SSc patients, probably caused by the microangiopathic damage of brain 
vessels [158].
Of note, central nervous system may be affected by microvascular damage as a complication 
of systemic involvement [159]. A higher risk for developing neurological complications is 
associated with circulating anti-U1 RNP (ribonucleoprotein) and ATA [160].
6.4. Carotid arteries
Regarding vascular morphology and function, carotid ATS has been detected in more than 
60% of scleroderma patients [40, 64, 161–163]. In line with this finding, the prevalence of 
carotid plaque, carotid wall thickening, and carotid artery stenosis has been showed to be sig-
nificantly higher in SSc compared to the general population of the same age and gender [66].
Some studies found no difference in CIMT values between scleroderma patients and controls 
[161, 164, 165], while others depicted increased CIMT in SSc patients [64, 166]. Nevertheless, 
significantly higher CIMT values in SSc demonstrating increased risk of ATS were found in 
less than half of the studies [8, 167]. The data interpretation may be hampered by small size 
of the cohorts enrolled and by variability of CIMT ultrasonographic measurement among 
studies [7].
CIMT values seem to directly correlate with disease duration, similarly to the observations 
in patients with RA, diabetes mellitus, or familial hypercholesterolemia [8]. High CIMT was 
variably associated with age, oxLDL [166], corticosteroid treatment [168], ACE gene polymor-
phism, and antibodies against human heat shock protein (HSP)-60, and mycobacterial HSP-65 
[166]. Increase in CIMT (≥0.10 mm) correlates with age- and sex-adjusted relative risk of 1.15 
for MI, and 1.18 for stroke [131].
SSc patients with plaques are characterized by increased concentration of serum proteins 
implicated in both vasculopathy, and fibrosis in comparison to patients without plaques [169].
7. Methods of detection
To elucidate the prevalence of PAD in SSc, several techniques, beside the physical examina-
tion (history of claudication or absence of pulses), have been employed. In particular, sur-
rogate markers of atherosclerotic damage have been demonstrated to be useful indicators of 
atherosclerotic wall damage. These include ankle brachial pressure index (ABPI) for arterial 
involvement of the lower extremities, blood pressure interarm difference (systolic/diastolic 
interarm difference) for proximal arterial disease of the upper extremities, and pulse wave 
velocity (PWV) and pulse wave analysis (PWA) to evaluate arterial stiffness. A novel non-
invasive tool to evaluate subclinical coronary ATS, a multidetector CT, generates a coronary 
calcium score, a surrogate marker for coronary ATS [170, 171].
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7.1. Intima-media thickness in SSc
Vessel intima-media thickness (IMT) is calculated by measuring the average thickness of the 
intima-media complex, the distance between the first and the second echogenic lines from 
the lumen [40, 64]. Carotid intima-media thickness (CIMT) as measured by high-resolution 
ultrasound is a well-validated marker of subclinical ATS. Increased CIMT has been shown to 
correlate with traditional CV risk factors, and to independently predict future vascular events 
in general population [64, 131].
A meta-analysis of CIMT in rheumatic diseases, including RA, SLE, and SSc, found signifi-
cantly increased values of CIMT in this population compared with healthy, age- and sex-
matched controls [167]. The pooled result of the SSc studies demonstrated a greater CIMT in 
SSc than in controls, suggesting an increased prevalence of subclinical ATS in both dcSSc and 
lcSSc [166, 172, 173]. The effect size seen in SSc was also greater than those in RA and SLE. 
Higher CIMT values are associated with increased age, but probably not with disease type, 
duration, or clinical characteristics [166].
In contrast to these findings, a number of individual studies have found no increase in CIMT 
in patients with SSc [40, 79, 161, 164, 165, 174]. Interestingly, there is also an anecdotal report 
of significantly lower CIMT in 10 SSc patients than in an age- and sex-matched control group 
without coronary risk factors [175].
7.2. Ultrasonographic evaluation and duplex scanning
SSc patients may have more severe, as well as more frequent, carotid disease (evaluating 
common carotid and its branches as well as the vertebral arteries) than the general population 
with similar rates of CV risk factors [66]. Carotid plaques are present in SSc, but probably 
not significantly more when compared to controls [161]. Evaluating other arteries using the 
ultrasonographic examination, the most impaired arteries in SSc are ulnar arteries, which are 
significantly narrower than those of the healthy controls. Other arteries are not significantly 
altered [176].
7.3. Flow-mediated dilation
Flow-mediated vasodilation (FMD) is usually evaluated by ultrasonographic measurement of 
artery diameter at baseline and maximal vasodilation following periodic ischemia, achieved by 
external cuff inflation [64]. FMD is calculated as a change in percentage following cuff release 
divided by baseline diameter [64]. The dilation is dependent on the endothelium function fol-
lowing the release of endogenous substance from endothelial cells, such as NO [70, 163, 177]. 
Endothelial dysfunction (as reflected by abnormally lower FMD values) is a key mechanism in 
predicting ATS involvement [63, 74].
Impaired FMD is associated with the presence of traditional CV risk factors [178], and is inde-
pendently predictive of incident CV events [179].
Many, but not all, studies have found FMD to be decreased in SSc compared with controls 
[8, 40, 64, 162, 163, 165, 172, 177, 180–182]. The results were independent of SSc type, disease 
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duration, clinical findings, and traditional CV risk factors [64]. On the other hand, unchanged 
FMD in SSc patients was reported as well [163].
It was suggested that increased levels of LpA in SSc patients cause impaired FMD, since LpA 
is capable of inhibiting inducible NO synthase [88].
7.4. Nitroglycerin-mediated dilation in SSc
Nitroglycerin-mediated dilation (NMD) is measured by evaluating the percentage of change 
of the arterial diameter from baseline following administration of 25–400 μg of sublingual 
nitroglycerin [40, 162]. Unlike FMD, the NMD value is independent of endothelium function 
[163].
Several studies have reported abnormally low NMD values in SSc patients. However, an 
impaired FMD was also demonstrated in SSc, while NMD was preserved [40, 70].
NMD values appear to be reduced in dsSSc with Raynaud's phenomenon compared to con-
trols [172, 180]. However, some studies did not find abnormal NMD in SSc patients [40, 163, 
165, 183].
Impaired NMD was found to correlate with increased age in SSc patients [40]. Reduced 
nitrate-mediated dilation [172, 180, 184] could suggest a coexisting functional or structural 
abnormality of arterial smooth muscle, adventitia, or both.
7.5. Ankle Brachial Pressure Index in SSc
Ankle Brachial Pressure Index (ABPI) is a validated diagnostic tool for PAD of the lower 
extremity. It is calculated by dividing the posterior tibial artery systolic pressure by the bra-
chial systolic pressure (both in mmHg) [66]. Normally ABPI equals 1.0, whereas abnormal 
ABPI is defined as a continuous variable less than 0.90 (American College of Cardiologist/
American Heart Association Practice Guidelines for Management of Patients with PAD). 
Increasingly lower values reflect an increased rate of arterial disease [66, 80]. According to 
the American Diabetes Association consensus paper, values lower than 0.9 are only mildly 
abnormal, and a ratio lower than 0.4 reflects a severe disease [185].
Several studies found that ABPI was more commonly abnormal in SSc patients.
Values of ABPI of 0.9–1.0 are described in about 60% of SSc patients, compared to 0–10% of 
general population with the same rate of CV risk factors [66]. When comparing the subsets of 
SSc, dcSSc may rather tend to have altered ABPI than lcSSc [143]. ABPI values remain stable 
in most SSc patients over time [186].
7.6. Arterial stiffness
Arterial stiffness is increased in the presence of CV risk factors [187], and is an independent 
predictor of CV events and CV and all-cause mortality across a wide range of patient popula-
tions [188]. This parameter performs as a well-validated surrogate marker of subclinical ATS, 
and an independent predictor of CV events and mortality [188].
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Arterial stiffness has been examined in SSc but with varying results [122, 162–165, 177, 189]. 
This parameter is measured by the techniques of pulse wave analysis (PWA), and pulse wave 
velocity (PWV). Carotid-femoral PWV is considered the current “gold-standard” measure-
ment of arterial stiffness [190]. PWA, expressed as the augmentation index (AI), reflects the 
stiffness of the aorta, whereas carotid-femoral PWV reflects the velocity of the pulse wave 
along the aortic and aortoiliac pathways. Increased arterial stiffness results in premature 
return of reflected waves in late systole, causing increased load on the left ventricle and 
increased myocardial oxygen demand [72].
Elevated values of PWA and PWV have been described in patients with dcSSc [162] and even 
more increased in patients with lcSSc. Moreover, PWV correlates positively with disease 
duration. Thus, it could be postulated that PWV may be a better measure of arterial stiffness 
than AI in SSc [122].
Arterial stiffness elevated in patients with SSc may correlate with elevated levels of soluble 
markers of endothelial activation, including plasma nitrate, soluble E-selectin, and soluble 
VCAM-1 [163].
However, microvascular disease or myocardial dysfunction may also contribute to the observed 
abnormality in AI [191]. SSc patients free from CVD were demonstrated to have higher AI, with 
respect to healthy controls. PWV, however, was not significantly increased. Interestingly, there 
was a paradoxical association between calcium channel blocker therapy and higher AI. This 
correlation may reflect generalized vasculopathy rather than atherosclerotic disease [192].
Significantly increased stiffness parameters (evaluating the macrovascular disease and sub-
clinical ATS) may correlate positively with ATA serum levels and inversely with ACA [193].
7.7. Angiography examination
Angiographic findings of the lower and upper extremity in SSc patients showed a correlation 
between CV risk factors and proximal, but not distal, PAD. The microvasculopathy related 
to disease pathogenesis may be considered the leading mechanism of peripheral vascular 
abnormalities in SSc according to a retrospective study of angiograms, when compared to 
atherosclerotic damage [142].
Taken together, these data suggest that SSc patients are more likely to develop PAD and 
scleroderma may be considered a risk factor of PAD.
8. Cardiac evaluation in SSc
8.1. Coronary artery evaluation
Angiographic evaluating of SSc patients with suspected coronary artery disease can reveal 
coronary artery disease, which seems to affect 22% of SSc patients. However, comparing 
the findings with the calculated standardized prevalence ratios according to Diamond and 
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Forrester’s probability analysis, the prevalence of coronary artery disease in SSc patients 
seems not to be larger than expected in patients without SSc [71].
A novel method of assessing coronary artery disease is the coronary calcium score, as deter-
mined by multidetector computed tomography. This technique measures coronary artery 
calcification that occurs in atherosclerotic plaque and has a good negative predictive value 
for CAD in the general population [194]. There is an evidence of higher presence of coronary 
calcification and higher coronary calcium score in patients with SSc compared to the healthy 
controls. Nevertheless, the correlation of coronary calcification with the angiographic find-
ings in SSc is unknown [74].
Coronary artery calcifications may represent the same process as the process of subcutaneous 
calcinosis in SSc. However, in SSc patients, who did not have any subcutaneous calcinosis, coro-
nary artery calcifications can be often detected as well [74]. Hence, subcutaneous calcinosis in 
SSc does not necessarily need to be associated with increased risk of coronary artery calcification.
8.2. Coronary flow reserve in SSc
Coronary flow reserve (CFR) is calculated by dividing the peak diastolic velocity during 
adenosine infusion, with the peak diastolic velocity at rest, and with a resting velocity time 
integral [195]. Abnormal CFR may reflect coronary artery disease or the incapability of micro-
circulation to supply the heart in cases of increased demand [134].
Several reports have found abnormal CFR in SSc patients. Reduced CFR alone cannot differ-
entiate vasospasm from anatomic arterial stenosis. Therefore, abnormal CFR in SSc does not 
necessarily imply the presence of atherosclerotic plaque [134]. Examination by myocardial 
multidetector CT may elucidate the relationship between CFR and coronary anatomy [196].
Assessing CFR in the left anterior descending coronary artery using contrast enhanced trans-
thoracic Doppler during adenosine infusion, even severe reduction can be detected in 50% of 
SSc patients, who have no heart disease symptoms [134, 195, 197].
Patients with dcSSc seem to have more severe reduction of CFR than lcSSc. Even younger 
dcSSc than lsSSc may suffer from worse damage of coronary arteries [195, 197].
8.3. Assessment of myocardial perfusion in SSc patients
Using 99m-Tc sestamibi gated myocardial perfusion SPECT with a stress-rest protocol 
reveals perfusion defects reported in 38% of SSc patients, which are probably not associ-
ated with age, sex, SSc subset or duration of Raynaud's phenomenon [198]. On the other 
hand, this perfusion defects may be associated with severe skin thickness, digital ulcers, and 
esophageal involvement [198].
Stress perfusion defects in cardiac MRI are common in asymptomatic SSc patients. There 
can be a non-segmental perfusion defect too, not corresponding to epicardial coronary artery 
distribution, which suggests microvascular impairment [199]. Most of SSc patients have at 
least one segmental MRI perfusion defect (e.g. reduced signal intensity or delayed wash-in) at 
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baseline [200]. Nifedipine can cause a significant increase in myocardial perfusion, according 
to an increased MRI perfusion index [200].
9. Prevention, management, and treatment of ATS in SSc
In general, early CV screening is mandatory in order to prevent and early treat vascular 
disease. A European League Against Rheumatism (EULAR) task force has published rec-
ommendations for screening, prevention and treatment of CVD in arthritis [47]. Similar 
recommendations regarding SLE and scleroderma are to follow soon [26]. According to the 
EULAR recommendations for inflammatory arthritis, CV risk assessment should follow 
the national guidelines, or in case of absence of such guidelines, Systemic Coronary Risk 
Evaluation (SCORE) function mode should be used [47]. Detection of CV risk includes labo-
ratory screening, physical examination (blood pressure, body composition, and body mass 
index), and non-invasive imaging methods [171].
9.1. Laboratory markers
Laboratory markers include: (1) the parameters of lipid metabolism: total cholesterol (TC), 
LDL, HDL, TC/HDL ratio, TG or LpA and oxLDL, both associated with ATS in autoimmune 
diseases [171]; (2) glucose metabolism alteration and insulin resistance: fasting glucose or oral 
glucose tolerance test [171, 201]; (3) acute phase reactants, hsCRP, and erythrocyte sedimenta-
tion rate (ESR), which are associated with the presence of subclinical ATS, CV events, and CV 
mortality [202–204].
The association of specific biomarkers of endothelial activation, markers of inflammatory 
pathways, and specific genes with ATS and increased CV risk have been described, for exam-
ple: cytokines (TNF superfamily and receptors for TNF, interferon gamma (IFNγ), interleukin 
6 (IL-6), IL-1, transforming growth factor beta 1 (TGF-β1)), chemokines, and adipokines [205].
Biologic markers of possible cardiac dysfunction such as brain natriuretic peptide (BNP) or 
N-terminal pro-BNP (NT-proBNP) are often elevated in patients with SSc [133]. Troponin 
has not been found to be elevated in SSc, so its elevated levels are suspected from non-sclero-
derma CVD or myopericarditis [206].
9.2. Non-invasive imaging methods
Screening non-invasive and imaging techniques include a broad spectrum of methods for 
detection of ATS: US of peripheral arteries, and especially of common carotid arteries to pro-
vide CIMT measurement and plaque detection, assessment of subclinical ATS (using ABPI, 
FMD, NMD, PWA, PVW, AI), assessment of cardiac disease (using coronary calcium score 
detected by CT, SPECT or PET, MRI, etc.), all of which were mentioned above [170].
9.3. Therapy
Beside the administration of vasculoprotective pharmacological agents, such as aspirin, 
statins, ACE inhibitors, and angiotensin II receptor blockers [47, 207–209], tight control over 
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the disease activity and inflammatory activity is needed, using low-dose corticosteroids, 
immunosuppressive agents, or biologics [43, 207, 208, 210, 211].
There are no specific recommendations for management of traditional risk factors, such 
as dyslipidemia, diabetes mellitus, or smoking in SSc patients. Their treatment mostly 
follows the national guidelines. According to the EULAR recommendations, statins, 
ACE inhibitors, and angiotensin II (AT-II) blockers are considered as preferred treatment 
options [47, 212].
Statins significantly reduce the risk of CV disease by lipid lowering effect and modulation of 
inflammatory pathways [213, 214]. Aspirin is used in general population to prevent the risk 
of CVD. Glitazones (peroxisome proliferator-activated receptor gamma, PPARγ agonists) are 
preferred in treatment of insulin resistance because of their potential vasculoprotective and 
anti-inflammatory effects [215].
The most severe complications (e.g. PAH and SRC) are treated according to the EULAR rec-
ommendations for SSc, with use of calcium channel blockers in case of PAH, and ACE inhibi-
tors in case of SRC [216]. Both of them, similarly as endothelin receptor antagonist (ERA) 
bosentan [217], have been demonstrated to have beneficial effects on myocardial perfusion, 
and on limiting further progression of life-threatening complications [200, 218, 219].
Nonsteroidal anti-inflammatory drugs (NSAIDs), administrated in pericarditis in SSc [216], 
are not recommended for long-term use with respect to the CV perspective [220].
To control the disease activity and inflammation, proper anti-inflammatory therapy should 
be administered. Corticosteroids and disease modifying antirheumatic drugs (DMARDs), 
used in some SSc manifestations according to the EULAR recommendation [216], may influ-
ence the CV risk.
Corticosteroids (used e.g. for treatment of myocarditis) may reduce vascular risk by effec-
tively suppressing systemic inflammation [47]. On the other hand, they are pro-atherogenic 
and lead to dyslipidaemia, diabetes and hypertension [220, 221]. A daily threshold dose of 
8 mg of prednisone was established, above which the number of deaths increases in a dose-
dependent manner [222]. Corticosteroids should be used at the lowest doses possible for the 
shortest period of time possible [47].
Methotrexate (MTX), recommended particularly to treat the skin manifestations, exerts 
bimodal effects on the vasculature. It increases the production of pro-atherogenic homo-
cysteine, which can promote endothelial injury, and increases LDL oxidation [223, 224]. On 
the other hand, hyperhomocysteinemia can be reversed by folate supplementation [225]. 
However, MTX may also be atheroprotective by inhibiting foam cell formation and modify-
ing reverse cholesterol transport [226]. In the EULAR cardiovascular recommendations for 
inflammatory arthritis, administration of MTX to the adequate control of disease activity is 
preferred to the possible negative CV effects of treatment [47].
Cyclophosphamide (CPA), used in treatment of ILD, induces cardiac damage and heart fail-
ure by its influence on the myocardial cells metabolism and induction of apoptosis [227]. 
According to experimental studies, CPA may influence the lipid metabolism [228], for exam-
ple, via the cholesterol transfer activity enhancement [229].
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Regarding the biologics, studies in CV effects are almost exclusively in RA, and these drugs 
are not commonly used in patients with SSc. Numerous recent studies concluded, that inflix-
imab, etanercept, adalimumab and rituximab may improve endothelial function and decrease 
CIMT and arterial stiffness in arthritis patients [208, 210, 211].
There may be differences among anti-TNF agents in terms of their effects on CV risk. There 
are controversial results on the effects of TNF blockers on lipid profiles, while infliximab may 
worsen the atherogenic index [211, 230]. On the other hand, biologics may also improve insu-
lin sensitivity, decrease resistin, and increase adiponectin production [211, 231]. Rituximab 
may also exert vasculoprotective effects [232–234].
10. Conclusion
Systemic sclerosis is a chronic, progressive, potentially lethal rheumatic disease. The manage-
ment and treatment of life-threating disease manifestations, such as pulmonary arterial hyper-
tension or scleroderma renal crisis, have improved over the last decades. Other causes, which 
increase the morbidity and mortality, have arisen, including the cardiovascular diseases in the 
first place. Similar to other rheumatic diseases, and based on many above-mentioned studies on 
pathogenesis of atherosclerosis in autoimmune conditions, cardiovascular risk in scleroderma is 
believed to be increased compared to the general population. The rate of this risk is not clear to 
date. Angiographic, sonographic, and computed tomography studies have provided conflicting 
data regarding the presence of macrovascular coronary lesions and accelerated atherosclerosis 
in scleroderma. Screening for subclinical cardiac involvement provides an opportunity for early 
diagnosis and treatment, which is crucial for positive outcome and prognosis. Thus, patients 
with systemic sclerosis should be closely observed, followed, and modifiable risk factors should 
be treated in the early stage. Moreover, future studies assessing larger cohorts of patients using 
standardized tools are needed to elucidate the cardiovascular risk in scleroderma patients.
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